AU2003259374A1 - Vaccine comprising il-13 and an adjuvant - Google Patents

Vaccine comprising il-13 and an adjuvant

Info

Publication number
AU2003259374A1
AU2003259374A1 AU2003259374A AU2003259374A AU2003259374A1 AU 2003259374 A1 AU2003259374 A1 AU 2003259374A1 AU 2003259374 A AU2003259374 A AU 2003259374A AU 2003259374 A AU2003259374 A AU 2003259374A AU 2003259374 A1 AU2003259374 A1 AU 2003259374A1
Authority
AU
Australia
Prior art keywords
vaccine
adjuvant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003259374A
Other languages
English (en)
Other versions
AU2003259374A8 (en
Inventor
Claire Ashman
Jonathan Henry Ellis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0220211A external-priority patent/GB0220211D0/en
Priority claimed from GB0304672A external-priority patent/GB0304672D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU2003259374A8 publication Critical patent/AU2003259374A8/xx
Publication of AU2003259374A1 publication Critical patent/AU2003259374A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2003259374A 2002-08-30 2003-08-28 Vaccine comprising il-13 and an adjuvant Abandoned AU2003259374A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0220211.7 2002-08-30
GB0220211A GB0220211D0 (en) 2002-08-30 2002-08-30 Vaccine
GB0304672A GB0304672D0 (en) 2003-02-28 2003-02-28 Vaccines
GB0304672.9 2003-02-28
PCT/GB2003/003721 WO2004019979A2 (en) 2002-08-30 2003-08-28 Vaccine comprising il-13 and an adjuvant

Publications (2)

Publication Number Publication Date
AU2003259374A8 AU2003259374A8 (en) 2004-03-19
AU2003259374A1 true AU2003259374A1 (en) 2004-03-19

Family

ID=31980002

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2003259374A Abandoned AU2003259374A1 (en) 2002-08-30 2003-08-28 Vaccine comprising il-13 and an adjuvant
AU2003260748A Abandoned AU2003260748A1 (en) 2002-08-30 2003-08-28 Il-14 vaccine for the treatment of asthma and atopic disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2003260748A Abandoned AU2003260748A1 (en) 2002-08-30 2003-08-28 Il-14 vaccine for the treatment of asthma and atopic disorders

Country Status (6)

Country Link
US (1) US20060104943A1 (enExample)
EP (2) EP1534323A2 (enExample)
JP (2) JP2006503018A (enExample)
AU (2) AU2003259374A1 (enExample)
CA (2) CA2496607A1 (enExample)
WO (2) WO2004019975A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101073590B1 (ko) * 2003-07-15 2011-10-14 메디뮨 리미티드 Ｉｌ-13에 대한 인간 항체 분자
PL1711528T3 (pl) 2003-12-23 2012-11-30 Genentech Inc Leczenie nowotworu nowymi przeciwciałami monoklonalnymi anty-IL13
US20070048785A1 (en) * 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
GB0600488D0 (en) * 2006-01-11 2006-02-22 Glaxo Group Ltd Immunoglobulins
SE532249C2 (sv) * 2006-11-13 2009-11-24 Theravac Pharmaceuticals Ab Nya formuleringar av IL-18 för behandling av olika inflammatoriska sjukdomar genom vaccinering
US9498525B2 (en) * 2007-03-15 2016-11-22 Hunter Immunology Limited Treatment or prophylaxis of asthma
WO2008109957A1 (en) * 2007-03-15 2008-09-18 Hunter Immunology Limited Method for determining suitability of treatment for asthma or chronic airways disease
BR112016004437A2 (pt) 2013-09-13 2017-10-17 Genentech Inc métodos de imunoteste e de seleção de linhagem de células, anticorpos e kit
CN105722532A (zh) 2013-09-13 2016-06-29 豪夫迈·罗氏有限公司 包含纯化的重组多肽的方法和组合物
EP3574915A1 (en) * 2018-05-29 2019-12-04 Neovacs Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity
AU2022212600A1 (en) * 2021-01-29 2023-08-17 Bayer Animal Health Gmbh Vaccine composition for breaking self-tolerance

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6296843B1 (en) * 1998-04-03 2001-10-02 The Penn State Research Foundation Mutagenized IL 13-based chimeric molecules
WO2000065058A1 (en) * 1999-04-23 2000-11-02 Pharmexa A/S Method for down-regulating il5 activity
EE200200025A (et) * 1999-07-20 2003-04-15 Pharmexa A/S Meetod GDF-8 aktiivsuse allareguleerimiseks, meetod looma lihasmassi suurendamiseks, GDF-8 analoog,immunogeenne kompositsioon, nukleiinhappefragment, vektor, transformeeritud rakk ja selle valmistamismeetod, kompositsioon GDF-8 vastaste antikehadeto
AU1599301A (en) * 1999-11-11 2001-06-06 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Modulating IL-13 activity using mutated IL-13 molecules that are antagonists or agonists of IL-13
US6846486B1 (en) * 2000-02-24 2005-01-25 Advanced Biotherapy Concepts, Inc. Method of treating allergy by administering an anti-histamine antibody
JP2004511527A (ja) * 2000-10-18 2004-04-15 グラクソスミスクライン　バイオロジカルズ　ソシエテ　アノニム ワクチン
GB0105360D0 (en) * 2001-03-03 2001-04-18 Glaxo Group Ltd Chimaeric immunogens
CA2496409A1 (en) * 2002-08-30 2004-03-11 Glaxo Group Limited Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use

Also Published As

Publication number Publication date
EP1534323A2 (en) 2005-06-01
JP2006503018A (ja) 2006-01-26
AU2003259374A8 (en) 2004-03-19
AU2003260748A1 (en) 2004-03-19
JP2006501249A (ja) 2006-01-12
AU2003260748A8 (en) 2004-03-19
WO2004019975A2 (en) 2004-03-11
CA2496607A1 (en) 2004-03-11
US20060104943A1 (en) 2006-05-18
EP1534329A2 (en) 2005-06-01
WO2004019979A2 (en) 2004-03-11
WO2004019975A3 (en) 2004-07-08
WO2004019979A3 (en) 2004-07-08
CA2496948A1 (en) 2004-03-11

Similar Documents

Publication Publication Date Title
AU2003262770A1 (en) Tri-gate devices and methods of fabrication
AU2003235707A1 (en) Immunogenic preparations and vaccines on the basis of mrna
AU2003242504A1 (en) Therapeutic tuberculosis vaccines
AU2003253859A1 (en) Interadermal delivery device, and method of intradermal delivery
AU2003270779A1 (en) Vaccine compositions and adjuvant
AU2002315166A1 (en) Sir2alpha-based therapeutic and prophylactic methods
AU2003258714A1 (en) Immune modulatory compounds and methods
AU2003269444A1 (en) An improved pacifier and method of use thereof
AU2002254558A1 (en) Novel vaccine
AU2003212369A1 (en) Improvements in vaccination
AU2002326751A1 (en) Immunoglobulin e vaccines and methods of use thereof
AU2003281044A1 (en) Pyrrolopyridine derivative and use thereof
AU2003225756A1 (en) Silica-based materials and methods
AU2003299823A1 (en) Methods of inducing and maintaining immune tolerance
AU2003259374A1 (en) Vaccine comprising il-13 and an adjuvant
AU2003296369A1 (en) Imminoamines and preparation thereof
EP1583557A4 (en) VACCINE COMPOSITIONS AND METHODS
AU2003267361A1 (en) Orthopoxvirus antigens and use thereof
AU2002347464A1 (en) Anti-arthropod vector vaccines methods of selecting and uses thereof
AU2003287802A1 (en) Palpometer and methods of use thereof
AU2003263895A1 (en) Contraceptive methods and formulations
AU2003273035A1 (en) Gene vaccine
AU2003300772A1 (en) Preventive and therapeutic aids vaccines
AU2003239773A1 (en) Preparation of vaccines
AU2002303093A1 (en) Mycobacterial vaccines

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase